

# Publications

---

## Publications

*\*corresponding author*

Aning, O.A. and Cheok, C.F.\*

Drugging in the absence of p53

***Journal of Molecular Cell Biology*** Oct 2018 (Special Edition)

Kumar, R., Coronel, L., Somalanka, B., Raju, A., Aning, O.A., An, O. Ho, Y.S., Chen, S., Mak, S.Y., Hor, P.Y., Yang, H., Lakshmanan, M., Itoh, H., Tan, S.Y., Lim, Y.K., Wong, A.P.C. Chew, S.H. , Huyhn, T.H. Goh, B.C., Tergoankar,V., Lim, C.Y., Cheok, C.F.\*

Mitochondrial Uncoupling reveals a novel therapeutic target for p53-defective cancers

***Nature Communications*** 2018 Sep 26;9(1)3931

highlighted in BioCentury Innovations, PharmaLive and A\*STAR Research Highlights, a Nature Springer journal

Kumar, R and Cheok, C.F.\*

PIAS4 regulates RIF1 functions for the maintenance of genomic stability

***Scientific Reports*** 2018 Mar 22;8(1):5236

Lim, S.H., Bhinge, A., Aksoy, I., Bragado, S., Aprea, J., Cheok, C.F., Calegari, F., Stanton, L.W., Kaldis, P.

CDK-dependent phosphorylation of Sox2 at serine 39 regulates neurogenesis,

***Molecular and Cellular Biology*** 2017 Jun 5. pii: MCB.00201-17.

Yeo, C., Alexander, I., Lin, Z.R., Lim, S.H., Aning, O.A., Kumar, R., Sangthongpitag,K., Pendharkar, V., Ho, V. H.B., Cheok, C.F.\* p53 maintains genomic stability by preventing interference between transcription and replication

***Cell Reports*** 2016 Apr 5;15(1):132-46

***Highlighted in Nature Reviews Molecular Cell Biology*** 2016 May 23;17(6):332.

Tan, E.Y. and Cheok, C.F.\*

Bringing p53 into the clinics

***Journal of Cancer Science and Therapy*** 2015 6:363-369

Kumar, R., Cheok, C.F.\*

Rif1: A novel regulatory factor for DNA replication and DNA damage response signaling  
***DNA Repair*** 2014 Mar;15:54-9

Cheok, C.F.\* and Lane, David Seeking synergy in p53 transcriptional activation for cancer therapy  
***Discovery medicine*** 2012 Oct;14(77):263-71

Lane, D.P. and Cheok, C.F.  
p53 pathway and Cancer Therapy  
***AACR Education Book*** 2012

Coffill, C.R., Muller, P., Oh, H.K., Neo, S.P., Hogue, K.A., Cheok, C.F., Vousden, K.H., Lane D.P., Blackstock, W.P, Gunaratne, J.  
p53 interactome reveals Nardilysin as a p53R273H-specific binding partner involved in invasion  
***Embo Reports*** 2012 Jun 29;13(7):638-44

Cheok, C.F.\*  
Protecting normal cells from the cytotoxicity of chemotherapy  
***Cell Cycle News and Views Cell Cycle.*** 2012 Jun 15;11(12):2227-8

Lane D.P. Brown C.J., Verma C.S., Cheok C.F.\*  
New insights into p53-based therapy  
***Discov Medicine*** 2011 Aug;12(63):107-17.

Brown C.J., Cheok C.F., Verma C.S., Lane D.P.  
Reactivation of p53: from peptides to small molecules.  
***Trends Pharmacol Sci.*** 2011 Jan;32(1):53-62.

Cheok, C.F., Verma, C., Lane, D.P. Translating p53 into the clinic  
***Nature Reviews Clinical Oncology*** 2011 Jan;8(1):25-37.

Cheok, C.F., Kua, N., Kaldis, P. and Lane, D.P.  
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.  
***Cell Death and Differentiation*** 2010 Sep;17(9):1486-500.  
highlighted in A\*STAR Research Highlights, 15 Sept 2010  
<http://www.research.a-star.edu.sg/research/6198>

Lane D.P., Brown C., Cheek C.F., Verma C.  
Applications of the inhibition of Mdm2 functions in cancer therapy  
***European Journal of Cancer Supplements*** 2010 Nov;8(7):22-23

Lane DP, Verma C, Cheek C.F\*.  
The p53 inducing drug dosage may determine quiescence or senescence.  
***Aging (Albany NY)*** 2010 Nov;2(11):748.

Lane D.P., Cheek C.F., Brown C., Madhumalar A., Ghadessy F.J., Verma C. Mdm2 and p53 are highly conserved from placozoans to man.  
***Cell Cycle*** 2010 Feb 4; 9(3)  
highlighted in Nature Research Highlights 2010 28 Jan;463:404)

Lane D.P., Cheek C.F., Brown C.J., Madhumalar A., Ghadessy F.J., Verma C.  
The Mdm2 and p53 genes are conserved in the Arachnids  
***Cell Cycle***. 2010 Feb 15;9(4):748-54.

Chew, J., Biswas, S., Shreeram, S., Humaidi, Wong, E.T., Dhillon M.K., Teo, H.L., Hazra, A., Cheek, C.F., Collazo, E.L., Bulavin, V., Tergaonkar, V.  
Wip1 phosphatase is a negative regulator of NFkB signaling.  
***Nature Cell Biology*** 2009 May;11(5):659-66.

Cheek, C.F.\* and Lane, D.P.  
New developments in small molecules targeting p53 pathways in anticancer therapy  
***Drug Development Research*** 2008 Dec 9;69(6):289-96  
Dey, A., Cheek, C.F., Wong, E.T., Tergaonkar, V., Lane, D.P.

R-Roscovitin simultaneously targets both the p53 and NF-kB pathway and causes potentiation of TNF $\mu$  induced apoptosis: Implications in cancer therapy  
***Cell Death and Differentiation*** 2008 Feb;15(2):263-73

Cheek, C.F.\*, Dey, A, Lane, D. P.  
CDK inhibitors sensitize tumor cells to nutlin-induced apoptosis  
***Molecular Cancer Research*** 2007 Nov;5(11):1133-45

Camus, S., Menendez, S., Cheek, C.F., Stevenson, L.F., Lain, S., Lane, D.P. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6.  
***Oncogene*** 2007 Jun 14;26(28):4059-70

Cheek, C.F., Wu, L., Janscak, P., Garcia, P.L., Hickson, I.D.

The Bloom's syndrome helicase promotes annealing of complementary single strands of DNA

***Nucleic Acids Res.*** 2005 Jul 15;33(12):3932-41

Cheek, C.F., Bachrati, C., Chan, K.L., Wu, L., Hickson, I.D.

Bloom's syndrome and the maintenance of genomic stability

***Biochemical Society Transactions*** 2005 Jul 15;33(12):3932-41

## **BOOK CHAPTERS**

Cheek, C.F and Lane, D.P.

Exploiting the p53 pathway for therapy Cold Spring Harbor Laboratory  
Perspectives in Medicine (The p53 Protein) 2016

Lane, D.P., Cheek, C.F., Lain, S.

p53 based cancer therapy Cold Spring Harbor  
Perspectives in Biology 2010 Sep;2(9):a001222.